Vivek Ramaswamy

Founder & CEO

Press Release

Roivant to Report Financial Results for the Quarter Ended December 31, 2021 on Monday, February 14, 2022

February 7, 2022 at 7:00 AM EST
  • Quarterly investor call and webcast scheduled for Monday, February 14 at 8:00 a.m. ET

  • Roivant will also present at the SVB Leerink Global Healthcare Conference in February, and the Truist AI Symposium and Cowen Healthcare Conference in March

BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV), a biopharmaceutical company dedicated to improving the delivery of healthcare to patients, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Monday, February 14, 2022 to report its third quarter 2021 financial results and provide a corporate update.

To access the live conference call, please dial +1-844-224-1923 (domestic) or +1-214-989-7105 (international) and use conference ID 8648616. A webcast of the call will also be available under “Events & Presentations” in the Investors section of the Roivant website at https://investor.roivant.com/news-events/events. The archived webcast will be available on Roivant’s website after the conference call.

Roivant also announced its participation in the following upcoming investor conferences:

  • SVB Leerink Global Healthcare Conference on Thursday, February 17, 2022 at 1:00 p.m. ET
  • Truist AI Symposium on Tuesday, March 1, 2022 at 10:10 a.m. ET
  • Cowen Healthcare Conference on Tuesday, March 8, 2022 at 9:10 a.m. ET

A live webcast of each presentation will be available under “Events & Presentations” in the Investors section of the Roivant website.

About Roivant Sciences
Roivant's mission is to improve the delivery of healthcare to patients by treating every inefficiency as an opportunity. Roivant develops transformative medicines faster by building technologies and developing talent in creative ways, leveraging the Roivant platform to launch 'Vants' – nimble and focused biopharmaceutical and health technology companies. For more information, please visit www.roivant.com.

Roivant Sciences Forward-Looking Statements
This press release may contain forward-looking statements regarding our or our management team's expectations, hopes, beliefs, intentions or strategies regarding the future, and statements that are not historical facts, including statements about the clinical and therapeutic potential of our product candidates, the availability and success of topline results from our ongoing clinical trials and any commercial potential of our product candidates.

Although we believe that our plans, intentions, expectations and strategies as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a number of risks, uncertainties and assumptions, including, but not limited to, those risks set forth in the Risk Factors section of our filings with the U.S. Securities and Exchange Commission. Moreover, we operate in a very competitive and rapidly changing environment in which new risks emerge from time to time. These forward-looking statements are based upon the current expectations and beliefs of our management as of the date of this press release, and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as required by applicable law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

The forward-looking statements in the webcast speak only as of the original date of the webcast. Roivant assumes no obligation to update forward-looking statements contained in the webcast as the result of new information or future events or developments.

Contacts:

Investors

Roivant Investor Relations
(646) 495-5310
ir@roivant.com

Media

Paul Davis
paul.davis@roivant.com